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Both spontaneous and inducible forms of chronic ur-
ticaria pose a significant economic burden and have 
an adverse effect on patients’ quality of life. The in-
ternational guidelines and US practice parameters 
for the diagnosis and management of chronic urtica-
ria both recommend performing a thorough patient 
history and physical examination, conducting limited 
routine laboratory testing, and taking a stepwise ap-
proach to treatment. These documents differ in several 
areas, such as the order of diagnostic procedures and 
the treatment for patients non-responsive to standard 
dose H1-antihistamines. Patients with chronic urticaria 
who visit a specialist have typically been treated with 
second-generation H1-antihistamines – the recom-
mended first-line treatments. The advantages and dis-
advantages of each treatment option should be taken 
into consideration when selecting therapies beyond 
H1-antihistamines. Greater awareness of the interna-
tional guidelines and US practice parameters will likely 
improve the quality of care for patients with chronic 
urticaria.
Key words: chronic spontaneous/idiopathic urticaria; physical 
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Urticaria is characterized by the presence of wheals (hives), angioedema or both, and is considered ch-
ronic if symptoms are present for 6 weeks or longer (1, 
2). Understanding the clinical manifestations associated 
with chronic urticaria (CU) and its subtypes, and the 
available treatments will improve diagnosis and better 
guide clinical management. Therefore, the objective of 
this article is to highlight the burden of CU, provide 
evidence-based recommendations to obtain an accurate 
diagnosis, and outline management strategies.
DISEASE OVERVIEW
CU can be broadly divided into urticarias, characterized 
by the spontaneous onset of signs and symptoms, or in-
ducible/physical urticaria, for which signs and symptoms 
arise following exposure to specific eliciting factors such 
as sustained pressure (delayed pressure urticaria) or hot 
or cold environments (heat- and cold-contact urticaria, 
respectively) (1, 2). It is possible, and in fact quite com-
mon, that two or more forms of CU coexist in the same 
patient (1, 2). 
Differences in terminology exist between the interna-
tional guidelines and the US practice parameters (1, 2). 
The international guidelines recognize two subtypes of 
CU: chronic spontaneous urticaria (CSU) and inducible 
urticaria (1). The US practice parameters include CU 
with physical triggers, CU for which a cause may be 
found, and chronic idiopathic urticaria (CIU; including 
autoantibody-associated urticarias) (2). The terms CSU 
and CIU are essentially synonymous in most cases and, 
as such, the term CSU is primarily used in this review 
because many cited studies were conducted outside of 
the US. 
Although the pathology of CU is not fully under-
stood, it is likely that mast cells, basophils, histamine, 
and other mediators play a key role (Fig. 1) (3–6). The 
release of histamine and other pro-inflammatory factors 
following degranulation of mast cells is regarded as the 
“final common pathway” in both physically induced CU 
and CSU, and forms the basis of H1-antihistamines as 
the first-line therapy for CU (4). However, the causative 
factors leading to degranulation of tissue-resident mast 
cells or basophils are less clear and likely differ between 
physically induced CU and autoimmune CU. The au-
toimmune response is thought to involve autoreactive 
IgE antibodies against auto-allergens, or autoreactive 
IgG antibodies against the mast cell (or basophil) high-
affinity receptor FcεRI, IgE, or both (4). The concept of 
a central role for IgE and FcεRI in priming mast cells 
(or basophils) for degranulation has led to the investi-
gation of novel treatments, such as omalizumab. In the 
US practice parameters, CIU is considered to have an 
autoimmune basis in many, but not all, patients, while 
other underlying causes of CIU that have been proposed, 
include infections, food intolerance and autoallergy (2, 
4). The international guidelines also identify potential 
causes such as auto immune disease, hypersensitivity 
reactions to food and drugs, and infections, but do not 
differentiate the etiology of CU subtypes (1).
Based on a survey conducted in Germany, the lifetime 
prevalence of CU was estimated to be 1.8% (7). CSU 
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consistently accounts for the majority of cases of CU, 
with reported estimates ranging from 66% to 93% (8). 
Many patients remain symptomatic beyond one year, with 
up to 14% of patients continuing to experience recurrent 
outbreaks of symptoms for longer than 5 years (9, 10). 
The impact of CU on quality of life (QoL) was found 
to be similar to the impact of ischemic heart disease in 
patients awaiting coronary artery bypass grafting and 
greater than respiratory allergy in patients with perennial 
rhinitis and intermittent asthma (11, 12). Impairment of 
QoL due to CU was reportedly worse than or similar to 
that observed with other skin diseases, including pso-
riasis, acne, or atopic dermatitis (13–15). The impact of 
CU on QoL has recently been highlighted in an Italian 
narrative medicine project (16). Based on data from 2004 
to 2006, the mean yearly direct and indirect costs of CSU 
in the US were estimated to be $244 million (17). Of the 
total annual cost, medication accounted for 62.5% and 
wages lost because of travel to outpatient visits/absences 
from work accounted for 15.7% (17). 
Impairment of QoL in CSU patients who also have a 
psychiatric comorbidity (e.g. depression and/or anxiety) 
has been reported to be greater than in those without a 
psychiatric diagnosis (18, 19). In a large population-ba-
sed study, autoimmune diseases (predominantly thyroid 
disorders) were significantly more common in patients 
with CU than in control patients without a diagnosis of 
CU (20). 
ROLE OF SPECIALISTS 
Well-designed clinical studies have provided evidence 
for the use of approved doses of second-generation H1-
antihistamines as the first-line therapy for CU, and there 
is broad consensus for such a treatment approach (1, 2). 
Despite this, a German survey of 776 physicians (43.0% 
dermatologists, 28.7% pediatricians, and 27.5% general 
practitioners [GPs]) carried out in 2009 revealed that a 
considerable proportion reported using sedating antihis-
tamines (23.0%) and oral corticosteroids (17.9%) as the 
first choice (21). Unfamiliarity with patient management 
guidelines may have contributed to this observation: 
physicians who indicated that they were aware of the in-
ternational guidelines were significantly less likely to use 
sedating antihistamines than those who were unaware of 
them (21). Although only one-third of physicians respon-
ded that they knew of the international guidelines, there 
was greater knowledge among dermatologists (50.6%) 
than among pediatricians (24.2%) and GPs (12.6%) (21). 
It is noteworthy that in Germany, it is common place for 
dermatologists to be dual trained in allergy. Therefore, it 
is possible that knowledge of patient management gui-
delines among US-based dermatologists may be lower 
than among German dermatologists.
A cross-sectional survey of 180 healthcare providers in 
the UK conducted in 2014 reported that 48 of 64 (75.0%) 
dermatologists used guidelines for the diagnosis and 
management of CU, compared with 50 of 55 (90.9%) 
allergists and immunologists. Among these physicians 
who reported using guidelines, the 2013 international 
guidelines were cited by a greater proportion of allergists/
immunologists (52.1%) than dermatologists (10.6%) 
(22). Despite this, and in contrast to the earlier German 
survey, all physicans reported using second-generation 
antihistamines as first-line treatment. 
In an online survey that assessed 80 Canadian der-
matologists’ perspectives of CU, most were using H1-
antihistamines as a first-line treatment (96.8%). Inte-
restingly, 16.1% of respondents reported > 50% of their 
patients had refractory CU, and the perceived next best 
Fig. 1. Pathogenesis of chronic urticaria (CU). CU signs and symptoms develop when skin mast cells or basophils degranulate and release histamine 
and other proinflammatory mediators. In chronic spontaneous urticaria, the degranulation of these cells in some patients is thought to be due to the 
effects of autoantibodies directed against a subunit of the high-affinity IgE receptor, FcεRIa, or to IgE itself. Other mechanisms of mast cell or basophil 
activation that are potentially relevant to CSU involve autoantigens and IgE directed against these autoantigens, as well as complement components, 
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add-on therapy was not consistent. Overall satisfaction 
with diagnosis and management of CU was low, but 
most (59.7%) were not familiar with the international 
guidelines (23).
The knowledge gap is further illustrated by data from 
a case-series study of referred patients in Denmark 
who, at presentation to a specialist urticaria clinic in 
2009–2011, were generally treated with insufficient 
doses of second-generation H1-antihistamines (24). The 
disease management guidelines also show clear consen-
sus on up-dosing second-generation H1-antihistamines 
in CSU patients who have failed to show sufficient 
response; however, it was again apparent from the Ger-
man survey that compared with GPs and pediatricians, 
dermatologists had the most experience with up-dosing 
these drugs (21). Nonetheless, even following standard 
and high doses of second-generation H1-antihistamines 
a number of patients remain antihistamine-resistant, 
and it is likely that dermatologists are best positioned to 
manage these patients. In the German physician survey, 
dermatologists were found to have more experience of 
alternative treatment options, such as dapsone and other 
immunosuppressants, which are of major importance in 
patients who do not respond to higher doses (21). Un-
derstanding what the treatment options are for patients 
with moderate-to-severe CSU is critical not only for the 
dermatologists for whom 65.5% of their patients fall into 
this severity, but also for GPs and pediatricians (with 
49.8% and 46.1% patients with moderate-to-severe CSU, 
respectively) (25). 
DIAGNOSIS AND TREATMENT GUIDELINES 
The international guidelines and US practice parameters 
both recommend a thorough patient history and physical 
examination, limited routine laboratory testing, and a 
stepwise approach to treatment, but they differ in several 
areas (Tables I, II) (1, 2). For example, the US practice 
parameters place greater emphasis on the limitations of 
laboratory testing, discuss treatment options not present 
in the international guidelines, and do not focus on eva-
luating treatment success (1, 2). 
It is worth noting that key similarities and differences 
between these two important guideline documents have 
also been considered previously (26). There are few 
major differences, but where they do occur, it tends to be 
driven by differences in expert opinion where guidance 
is provided in the absence of strong scientific evidence 
(26). Needless to say global consensus activities relating 
to urticaria are ongoing.
DIAGNOSIS
The characteristic skin finding of CU is the presence 
of hives that typically manifest as edematous, pink or 
red, pruritic wheals of variable size and shape, and lack 
any epidermal changes such as scale/crust. Individual 
lesions are evanescent and typically fade within 24 h. 
Angioedema generally involves swelling of the lower 
dermis and subcutis, with frequent involvement of the 
proximal mucus membranes (ocular or lip edema) or se-
Table I. Comparison of diagnostic recommendations in the international guidelines and the US practice parameters for the diagnosis and 
management of chronic urticaria (CU)
EAACI/GA2LEN/EDF/WAO international guidelines (1)
US practice parameters for the diagnosis 
and management of CU (2)
Thorough patient history and 
physical examination
History includes psychosomatic and psychiatric disease, surgical implantations, 
and events after surgery
No major differences from international 
guidelines
Routine laboratory evaluation Very limited routine diagnostic measures (CBC with differential, ESR and/or CRP 
level)
Testing should be selective. For patients with 
CU without atypical features consider: CBC 
with differential, ESR and/or CRP level, liver 
enzymes, TSH; clinical utility of using these 
tests routinely has not been established
Tests for the identification of 
underlying causes of CSU based 
on patient history
Based on patient history (in no preferred order): 
test for infectious diseases (e.g. Helicobacter pylori), type I allergy, functional 
autoantibodies, thyroid hormones and autoantibodies, tryptase as indication 
of severe systemic disease; perform skin tests including physical tests and/or 
lesional skin biopsy; trial pseudoallergen-free diet for 3 weeks; conduct ASST
Limited laboratory testing, routine testing 
rarely yields clinically significant findings 
Tests for differential diagnosis Depending on patient history:
• If autoinflammatory disease is strongly suspected, consider: ESR and/or 
CRP level; testing for paraproteinemia (adults); screening for neutrophil-rich 
infiltrates in skin biopsy; performing gene mutation analysis for hereditary 
periodic fever syndromes
• If HAE is suspected, test for complement C4, C1-INH levels and function, and 
C1q and C1-INH antibodies 
• If history suggests HAE and former tests are unremarkable, perform gene 
mutation analysis
• If mean wheal duration is >24 h, perform biopsy of lesional skin to assess 
for signs of urticarial vasculitis (damage to small vessels in the papillary 
and reticular dermis and/or fibrinoid deposits in perivascular and interstitial 
locations)
Based on patient circumstances, history and 
physical exam consider: 
• Skin biopsy
• Physical challenge tests
• Complement activity tests
• Stool analysis (ova and parasites)
• Urinalysis 
• Hepatitis B and C serologies 
• Chest radiography and/or imaging studies 
• Anti-nuclear antibody, rheumatoid factor 
and/or anti-citrullinated protein
• Cryoglobulin levels
• Serologic and/or skin testing for immediate 
hypersensitivity 
• Thyroid autoantibodies to: TSH receptor, 
thyroglobulin, thyroid peroxidase, and 
sodium/iodine symporter
• Serum protein electrophoresis
ASST: autologous serum skin test; C1-INH, C1-inhibitor; CBC: complete blood count; CRP: C-reactive protein; CSU: chronic spontaneous urticaria; EAACI: European 
Academy of Allergy and Clinical Immunology; EDF: European Dermatology Forum; ESR: erythrocyte sedimentation rate; GA2LEN: Global Allergy and Asthma European 
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vere peripheral edema. Severe swellings may be painful, 
and most cases of angioedema typically may take up to 
72 h to resolve (1, 2). 
As shown in Table I, it is universally recommended 
to begin the diagnostic process with a thorough patient 
history and physical examination (1, 2). Where indicated 
by patient history, provocation tests (e.g. exposure to cold 
stimulus if cold-contact urticaria is suspected, or use of 
a dermographometer to elicit symptomatic dermograp-
hism) can be used to confirm the relevance and threshold 
of triggers in patients who have a physical/inducible form 
of CU (Table II) (1, 2). It is important to note that not 
all possible causative factors need be investigated in all 
patients (1). For example, efforts to identify underlying 
causes should be limited to patients with longstanding 
and/or severe CSU, although it is important to counsel 
patients that identifying causes is highly unlikely in the 
majority of CSU cases (2). 
Recommended diagnostic tests and tools may identify 
CU subtypes and narrow down the differential diagnosis 
(Table III), but the recommendations are slightly diffe-
rent in each guideline (Table I) (1, 2). Skin biopsies are 
not necessary for most cases of refractory CU and should 
be considered only when vasculitis, auto-inflammatory 
disease or another immunologic condition that can 
present with hive-like lesions (e.g. bullous pemphigoid, 
etc.) is suspected (2). 
TREATMENT 
Approved doses of second-generation H1-antihistamines 
are the universally recommended first-line therapy for 
CU (1, 2), based on demonstrated efficacy in double-
blinded clinical studies (27–31). Because there are not 
enough comparative studies to identify a preferred agent 
(1, 2) and individual patients may respond differently 
to treatment (32), selection must be based on physician/
patient discretion. A progressive increase to up to 4-fold 
the standard dose is recommended for patients who do not 
respond to approved doses (1, 2). Studies have shown that 
increasing the antihistamine dose may improve control 
of CU symptoms, but data for some antihistamines are 
limited and conflicting (33–41).
In our experience, approximately 50% of all patients 
with CSU respond to antihistamines at standard doses 
and another 10–25% will respond with up-dosing, but 
at CSU referral centers as many as 96% of patients have 
failed antihistamines even at high doses (42). However, 
it is important to confirm that the patients have been 
compliant with the treatment dose and schedule, and 
that their response is inadequate (43–45). As indicated 
by both the international guidelines and US practice pa-
rameters, additional treatment options are available for 
patients who do not respond to monotherapy (Fig. 2) (2). 
Although not included in the international guidelines, the 
US practice parameters recommend adding an additional 
second-generation H1-antihistamine and/or H2-antagonist 
to H1-antihistamine therapy (step 2). Data comparing 
the efficacy and safety of combination therapy versus 
up-dosing of a single agent are scarce (46, 47), but, as 
a general principle, it is likely to be safer to adjust the 
dosing of a single drug rather than complicating mana-
gement with several antihistamine classes (48). 
First-generation antihistamines have similar efficacy, 
but greater sedation and impairment compared with 
second-generation antihistamines, and should therefore 
be used with caution (1, 2, 28, 29). The US practice pa-
rameters recommend the use of first-generation antihista-
mines at bedtime in order to reduce daytime impairment 
(2); however, they have been shown to frequently lead 
to daytime somnolence, sedation, drowsiness, fatigue 
and impaired concentration and memory, especially if 
Table II. Comparison of recommendations for confirming the relevance and threshold of triggers for inducible chronic urticaria (CU) in 
the EAACI/GA2LEN/EDF/WAO international guidelines and the US practice parameters for the diagnosis and management of CU
EAACI/GA2LEN/EDF/WAO international guidelines 
US practice parameters for the diagnosis and management 
of CU (2)
Cold urticaria Cold provocation and threshold test
Extended: CBC with differential, ESR and/or CRP level, cryoproteins 
Apply cold stimulus (e.g. ice cube on forearm) and observe for 
wheal-and-flare reaction during skin rewarming
Delayed pressure urticaria/
angioedema
Pressure and threshold test Challenge with a 15 lb (6.8 kg) weight suspended over shoulder 
for 10−15 min and monitor for angioedema development
Heat urticaria Heat provocation and threshold test Does not include as a separate subtype; patients with lesions in 
response to heat are categorized as having cholinergic urticaria
Solar urticaria UV and visible light of different wavelengths and threshold test
Extended: Rule out other light-induced dermatoses
Phototest to various wavelengths of light
Symptomatic 
dermatographism
Elicit dermographism and threshold test (dermographometer)
Extended: CBC with differential, ESR and/or CRP level
Stroke skin with firm object (e.g. tongue blade or other 
instrument with a firm edge) or a dermographometer
Vibratory angioedema (97) Test with vortex Expose to a vortex mixer
Aquagenic urticaria Wet cloth (body temperature) for 20 min Water compress (35°C) applied to the upper body for 30 min
Cholinergic urticaria Exercise and hot bath provocation Provocative challenges that increase core body temperature 
(e.g. exercise, hot water immersion, or methacholine 
intradermal challenge)
Exercise-induced urticaria Considered a form of anaphylaxis, not urticaria Exercise challenge in a setting prepared for anaphylaxis 
management 
Contact urticaria Cutaneous provocation test. Skin tests with immediate readings, for 
example prick test
Cutaneous provocation test, skin test with immediate readings 
such as prick test
CBC: complete blood count; CRP: C-reactive protein; EAACI: European Academy of Allergy and Clinical Immunology; EDF: European Dermatology Forum; ESR: erythrocyte 
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taken late at night (49). H2-antihistamines, specifically 
cimetidine, used in combination with H1-antihistamines 
have shown a limited additive effect, and are, therefore, 
no longer recommended by the international guidelines 
(50–52). 
In the international guidelines and the US practice 
parameters, patients are considered to have refractory CU 
based on the absence of clinical response to antihistamine 
therapy. However, the international guidelines consider 
the threshold to be up to 4 times the approved dose of 
antihistamines, whereas the US practice parameters con-
sider it to be maximal combination antihistamine therapy 
(1, 2). Similarly, the treatment course for patients non-
responsive to antihistamine treatments differs between 
the international guidelines and US practice parameters 
(1, 2). For these patients, a number of treatment options 
are available, several of which have evidence from at 
least one double-blind randomized controlled trial that 
supports their use (Table IV) (1, 2, 45, 53, 54).
Oral corticosteroids are frequently used in patients 
with CU not adequately controlled with antihistamine 
therapy, yet no controlled study has been performed 
(2, 55). A large retrospective study found that 50% of 
patients with antihistamine-resistant CU treated with a 
single course of prednisone (25 mg/day for 3 days, de-
escalated to 12.5 mg/day for 3 days and 6.25 mg/day for 
4 days) had a remission, and an additional 9% responded 
after a second course (56). The main concern with the 
use of corticosteroids is the risk of adverse effects, thus 
only short-term use to help manage exacerbations should 
be considered (1, 2). 
Leukotriene-modifying agents (LTMAs) such as 
montelukast and zafirlukast, are reportedly effective for 
the treatment of CU as monotherapy or in combination 
with H1-antihistamines, with the strongest evidence for 
montelukast (10 mg/day), although the treatment effect 
observed was small (57–65). Results of clinical studies 
have been inconsistent; some showing superiority (60, 
64, 65), and others demonstrating inferior responses from 
LTMAs compared with antihistamines (61), or even a 
lack of efficacy compared with placebo (66). 
Agents with H1- and/or H2-antagonist activity such as 
hydroxyzine, cyproheptadine, or doxepin are also options 
for patients whose symptoms do not respond to prior 
antihistamine therapy, but they have considerable seda-
ting effects (1, 2). Compared with other antidepressants 
Table III. Conditions to consider in the differential diagnosis of chronic urticaria (CU)
 Differentiating features
Common
Anaphylaxis Generalized wheals/angioedema and involvement of multiple organs other than skin, such as 
pulmonary tract, gastrointestinal, nervous, or cardiac systems
Autoimmune thyroid disease Thyroid orbitopathy, swelling of area between upper eyelids and eyebrows, and appearance of 
angioedema of upper eyelids 
Bullous pemphigoid Pruritic papules and plaques that develop into tense subepidermal blisters 
C1-inhibitor deficiencies Recurrent angioedema without wheals
Contact dermatitis Persistent angioedema of lips; symptoms associated with exposure to stimulus (e.g. poison ivy, 
nickel) 
Cutaneous and systemic lupus erythematosus Biopsy shows leukocytoclastic vasculitis 
Cutaneous mastocytosis Skin lesions that urticate when stroked
Food/insect allergies Urticaria develops following exposure 
Angioedema with ACE or DPP IV inhibitors (98) Angioedema without urticaria including laryngeal edema that presents with very large lip edema and 
tongue edema; can present even after months or years of therapy 
Polymorphous light eruption Clustered pruritic papules and plaques appearing within minutes to hours of exposure to sunlight; 
duration of approximately several days
Urticarial vasculitis Lesions do not blanch (e.g. petechial/purpuric), are more commonly associated with symptoms of 
burning or pain than pruritus; heal with residual hyperpigmentation; joint pain, fatigue, or shortness 
of breath possible; duration >24 hours; diagnosis involves biopsy
Less common or uncommon
Autoimmune progesterone-associated dermatoses, including 
catamenial dermatoses 
Develops 3−10 days before menses; can present with lesions that look like eczema, erythema 
multiforme, bullous disease, or folliculitis
Autoinflammatory syndromes:
Familial cold-autoinflammatory syndrome Erythematous papules and plaques that can last >24 h, fever, arthralgia and conjunctivitis 1–2 hours 
after exposure to cold, negative responses to cold challenge
Muckle-Wells Renal abnormalities, progressive deafness 
NOMID Signs of bony overgrowth, mental retardation, papilledema
Hyper-IgD syndrome, TRAPS, PFAPA, PAPA Present with fever
FMF Erysipelas-like lesions on lower extremities; fever, arthralgias, serositis without adenopathy; 
presents in patients of Mediterranean heritage; duration of approximately 3 days
Cryoglobulinemia Palpable purpura/petechiae on lower extremities; brawny edema of lower legs
Episodic angioedema with eosinophilia (Gleich syndrome) Episodic attacks of profound angioedema with weight gain
Schnitzler syndrome Long-lasting urticarial wheals occurring in association with intermittent fevers, bone pain, arthralgias, 
myalgias, and IgM > IgG gammopathy 
Urticaria-like dermatoses of pregnancy:
Gestational pemphigoid Abrupt onset of pruritic papular urticaria, initially on trunk, becomes generalized and blisters
PUPPP Pruritic papules begin within abdominal striae during third trimester of first pregnancy, sparing the 
face, hands, and soles of feet
ACE: angiotensin-converting enzyme; CBC: complete blood count; DPP IV: dipeptidyl peptidase-4; FMF: familial Mediterranean fever; hyper-IgD: hyper-immunoglobulin 
D syndrome with periodic fever; NOMID: neonatal-onset multisystem inflammatory disease; PFAPA: periodic fevers with aphthous stomatitis, pharyngitis, and adenitis; 
PAPA: pyogenic arthritis, pyoderma gangrenosum, and acne syndrome; PUPPP: pruritic urticarial papules and plaques of pregnancy; TRAPS: tumor necrosis factor 
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such as amitriptyline, nortriptyline, and mirtazapine, 
clinical evidence is strongest for doxepin (at doses from 
10 mg to 25 mg 3 times daily) (2, 32, 67–69); however, 
sedation, electrocardiographic effects at doses >100 mg, 
and numerous drug–drug interactions may limit its use 
(2, 70, 71).
Of the available agents recommended for patients with 
refractory CU, omalizumab (Xolair®, Genentech, Inc.; 
San Francisco, CA), an anti-IgE antibody, has the most 
robust data supporting its use (45), and as of February 
2016 is the only agent approved by the US Food and Drug 
Administration and the European Medicines Agency for 
the treatment of adults and adolescents who have refrac-
tory CIU and CSU, respectively (72, 73). Although oma-
lizumab (administered as subcutaneous injections every 
4 weeks at doses of 150 mg, or 300 mg) has a favorable 
risk/benefit ratio and was well tolerated in clinical studies 
(74–76) it has infrequently been associated with ana-
phylaxis (72, 76). Omalizumab has also been 
shown to be an efficacious treatment alone or 
as an add-on therapy to H1-antihistamine plus 
an H2-antihistamine or LTMA, or a combina-
tion of these for patients with CIU refractory 
to antihistamine treatment in 3 Phase 3 studies 
(74–76). However, the cost of treatment, the 
requirement for subcutaneous administration 
in a physician’s office and anaphylaxis con-
cerns may limit its use (2, 45). 
In addition to omalizumab, both the interna-
tional guidelines and the US practice parame-
ters recommend consideration of cyclosporine 
A (CsA) for patients with refractory CU (1, 2). 
CsA is an immunosuppressant that has been 
shown to be an effective treatment for CU (at 
dosages of 3–5 mg/kg/day for up to 4 weeks) in 
placebo-controlled studies as a solo treatment 
and in combination with second-generation 
H1-antihistamines (77, 78). Treatment with 
CsA is associated with a relatively high 
incidence of mild adverse effects including 
gastrointestinal disturbances, paresthesia and 
infections (77, 78); retrospective study showed 
that adverse effects were generally mild and 
transient for patients with CU using low-dose 
CsA (< 3 mg/kg/day) for up to 10 years (79). 
However, long-term, low-dose CsA treatment 
is known to be associated with nephrotoxicity 
(80). Clinicians need to carefully consider 
whether CsA is an appropriate treatment option 
based in part on a patient’s comorbidities. For 
example, subjects with hypertension and/or 
renal insufficiency would not be a good can-
didate for CsA treatment. It is also important 
to be aware that there are clinically important 
differences in bioavailability between CsA 
preparations (2, 81, 82).
Additional anti-inflammatory agents and immunosup-
pressants can be considered for patients with refractory 
CU (2), but there is limited evidence supporting the use 
of these agents (44, 83, 84). Anti-inflammatory agents, 
including dapsone, sulfasalazine, hydroxychloroquine 
and colchicine, have limited evidence for efficacy in CU 
(2), but a recent double-blind, placebo-controlled study in 
patients with CSU indicates dapsone 100 mg/day led to 
a significant improvement of symptoms (85). It remains 
to be confirmed whether these agents are more effective 
in patients with neutrophil-rich urticaria. An open study 
reported that among CU patients with neutrophilic skin 
inflammation, 8 of 9 treated with colchicine and 3 of 3 
treated with dapsone showed a response (2, 86). Other 
immunosuppressants to consider include tacrolimus, 
mycophenolate and methotrexate, but clinical evidence 
supporting their use is very low (2). Case reports sug-
gest that the anti-CD20 biologic, rituximab, may also 
Fig. 2. Chronic urticaria treatment algorithm. A) European Academy of Allergy 
and Clinical Immunology/Global Allergy and Asthma European Network/ European 
Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) international 
guidelines and B) the US practice parameters for the diagnosis and management of 
chronic urticaria (CU). NSAID: non-steroidal anti-inflammatory drug. Adapted from 
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provide some benefit (87). A recent publication assessing 
treatment response in relation ship to CU characteristics 
may be useful for selecting treatment regimens (57). 
More studies, especially randomized controlled trials, 
are needed to confirm the clinical improvement seen 
with these off-label therapies, as well as comparative 
effectiveness studies of both FDA-approved and off-label 
therapies. There is still an unmet need for new, more ef-
fective therapies to treat patients with refractory CU and 
with this greater refinement of which CU sub-phenotypes 
will respond best to which therapy. 
EVALUATING TREATMENT SUCCESS
The goal of CU treatment is to achieve substantial impro-
vements in symptoms with limited adverse effects (1). 
It is important to measure the patient’s urticaria activity 
at baseline, and during subsequent visits to the clinic in 
order to objectively assess the response to treatment(s). 
The Urticaria Activity Score (UAS) is a validated tool 
(87, 89) that has been used frequently for measuring 
and monitoring disease activity in clinical studies of 
urticaria and clinical practice (1, 74–77, 90, 91). In the 
international guidelines, the sum of the patient-reported 
UAS over 7 days (UAS7) is the recommended approach 
for assessing treatment success in CSU (Table I) (1, 88). 
The Urticaria Control Test (UCT) is an alternative 
patient-reported instrument validated for retrospective 
assessment of any CU subtype using 4 questions (92). 
Visual analog scales can also be used to assess disease 
severity and response of symptoms to treatment that are 
difficult to measure objectively, such as itch intensity 
(93). 
Because of the significant impact CU has on QoL, 
assessing QoL is an important aspect of monitoring di-
sease activity (1). The Dermatology Life Quality Index 
(DLQI) is a validated 10-question tool to compare QoL 
in patients with a variety of skin conditions that has cor-
related positively and significantly with UAS (15, 88). 
The Chronic Urticaria Quality of Life Questionnaire 
(CU-Q2oL) is a validated QoL tool and the only disease-
specific QoL instrument recommended for patients with 
CSU (1, 89, 94, 95). The UAS and CU-Q2oL should be 
used to measure the effects of change in CSU disease 
activity rather than non-validated tools (96). 
CONCLUSION 
CU is a complex disorder that has a substantial econo-
mic burden and a significant impact on patients’ QoL. A 
complete history and physical examination will ensure 
the accurate diagnosis of CU and will determine the 
extent of laboratory studies needed for each indivi-
dual patient. Many patients may respond adequately to 
approved doses of second-generation H1-antihistamines, 
which should be first-line therapy. For those who does 
not achieve significant clinical improvement, the advice 
is to increase the dose of these non-sedating antihista-
mines to up to 4 times the approved dose. The authors 
recommend using one antihistamine in this category for 
the dose escalation rather than double the dose of two 
different second-generation antihistamines. During this 
dose escalation the addition of a sedating antihistamine 
in the evening can also be effective, but combining a 
non-sedating antihistamine and a sedating antihista-
mine is not recommended by all experts or the EAACI/
GA2LEN/EDF/WAO guideline. If dose modulation of 
the first- and second-generation antihistamines do not 
significantly improve the CU and/or if the side effects 
needed to achieve this level of clinical improvement are 
Table IV. Agents with at least one double-blind randomized controlled trial supporting its use for patients with refractory chronic urticaria 












Montelukast 10 mg daily 2–4 weeks Low Multiple RCTs 
(mixed results) 
(61, 65)
Minimal (B) None $$ Unknown
Dapsone 100 mg daily 
with reduction of 
dose as tolerated
1–6 weeks Moderate 1 RCT (85) Low-moderate (C) Baseline: G6PD, CBC, 
LFT; Monthly: CBC, 
LFT ×6 months then 
periodically
$ Possible 
Zafirlukast 20 mg twice 
daily (53)
Several days 
to 1 week (53)
Low 2 RCTs (negative 
results) (60, 66)









Omalizumab 150–300 mg 
every 4 weeks
1–2 weeks High 5 RCTs (74–76, 90, 
101)
Low-moderate (B) None $$$$ Unknown
aCategory B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women; Category 
C: animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may 
warrant use of the drug in pregnant women despite potential risks. bCost ratings are based on comparison with each agent with $ being the least expensive and $$$$ 
the most expensive. cInduction of remission that was based on reports of resolution of urticaria after therapy has been discontinued. 
BUN: blood urea nitrogen; CBC: complete blood count; Cr: creatinine; CsA: cyclosporine A; G6PD: glucose-6-phosphate dehydrogenase; LFT: liver function test; Mg: 
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unacceptable then one should consider the addition of 
omalizumab. If omalizumab fails, is not well tolerated 
or unavailable, alternate options should be considered: 
CsA, dapsone, colchicine, mycophenolate, sulfasalazine, 
rituximab or leukotriene antagonists. Of these options the 
evidence of clinical effectiveness is most robust for oma-
lizumab and to a lesser extent CsA. The advantages and 
disadvantages of each of these options should be taken 
into consideration when selecting an appropriate therapy. 
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